The utility of faecal calprotectin to predict post-operative recurrence in Crohńs disease

Bachiller, María Teresa Herranz; Barrio, Jesús; Salazar, Luis Fernández; Ruiz-Zorrilla, Rafael; Val, L Sancho del; Sánchez, R

doi:10.3109/00365521.2015.1130164

Cited by 18 publications

(15 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the retrospective study by Herranz Bachiller et al[ 105 ] 97 patients with CD and ileocolic resection who had undergone FC measurement and subsequent ileo-colonoscopy were included. FC was related to endoscopic recurrence more than any clinical or serological parameters.…”

Section: Fc In Ibdmentioning

confidence: 99%

From bench to bedside: Fecal calprotectin in inflammatory bowel diseases clinical setting

Mumolo

Bertani

Ceccarelli

et al. 2018

WJG

140

116

View full text Add to dashboard Cite

Fecal calprotectin (FC) has emerged as one of the most useful tools for clinical management of inflammatory bowel diseases (IBD). Many different methods of assessment have been developed and different cut-offs have been suggested for different clinical settings. We carried out a comprehensive literature review of the most relevant FC-related topics: the role of FC in discriminating between IBD and irritable bowel syndrome (IBS) and its use in managing IBD patients In patients with intestinal symptoms, due to the high negative predictive value a normal FC level reliably rules out active IBD. In IBD patients a correlation with both mucosal healing and histology was found, and there is increasing evidence that FC assessment can be helpful in monitoring disease activity and response to therapy as well as in predicting relapse, post-operative recurrence or pouchitis. Recently, its use in the context of a treat-to-target approach led to a better outcome than clinically-based therapy adjustment in patients with early Crohn’s disease. In conclusion, FC measurement represents a cheap, safe and reliable test, easy to perform and with a good reproducibility. The main concerns are still related to the choice of the optimal cut-off, both for differentiating IBD from IBS, and for the management of IBD patients.

show abstract

Section: Fc In Ibdmentioning

confidence: 99%

From bench to bedside: Fecal calprotectin in inflammatory bowel diseases clinical setting

Mumolo

Bertani

Ceccarelli

et al. 2018

WJG

140

116

View full text Add to dashboard Cite

show abstract

“…However, there is no agreement on the best cutoff value to select patients who may profit from short‐interval endoscopic examinations. In this respect, FC cutoff levels ranging from 60 to 200 μg/g have been suggested by different authors, showing 63–95% sensitivity and 54–91% specificity …”

Section: Resultsmentioning

confidence: 96%

“…Moreover, the quality of the studies is more uniform than in the other sections of this review. All but two studies had a prospective design (Table S1), and in all cases but one, the definition of POR was based on the Rutgeerts score, rendering conclusions more reliable despite the small sample size of most series (Table ).…”

Section: Resultsmentioning

confidence: 99%

Is fecal calprotectin an accurate marker in the management of Crohn's disease?

Vernia

Ruscio

Stefanelli

et al. 2019

J of Gastro and Hepatol

View full text Add to dashboard Cite

Although lacking validated cutoff values, fecal calprotectin (FC), besides C‐reactive protein, is considered the standard test for assessing disease activity in Crohn's disease (CD). The aim of the present review is to provide a general overview of the literature addressing the role of FC in the clinical and endoscopic assessment of disease activity in CD, seeking correlations with capsule endoscopy, response to therapy, prediction of relapse, and postoperative recurrence. A systematic search of the literature up to September 2019 was performed using Medline, Embase, and the Cochrane Library. Only papers written in English concerning FC in adult patients affected by CD were included. Pediatric studies, in vitro studies, animal studies, studies on blood/serum samples, and studies analyzing FC in ulcerative colitis or in both CD and ulcerative colitis were excluded. Out of 713 citations, 65 eligible studies were identified. FC showed high accuracy in the assessment of intestinal inflammation and response to therapy, in particular in colonic disease, thus proving a good surrogate marker for these aims. FC is useful in identifying patients at high risk for endoscopic relapse or postoperative recurrence, for optimizing or downstage therapy. Unfortunately, FC performs less well in small bowel CD. FC is an effective fecal marker in the management of CD patients, optimizing the use of endoscopic procedures. Owing to its diagnostic accuracy, FC may represent a cornerstone of the “treat‐to‐target” management strategy of CD patients.

show abstract

“…Those patients in the ‘amber’ or intermediate range between these two cut-offs were followed up more closely. The advantage of the care pathway is that it is simple and workable in supporting clinical decision making, being applied to all Crohn's disease phenotypes and to postsurgical patients since mucosal disease is common to all 26. It is applied only once patients are established on maintenance therapy, whether the patient is symptomatic or not.…”

Section: Discussionmentioning

confidence: 99%

Validation of a care pathway for the use of faecal calprotectin in monitoring patients with Crohn's disease

Turvill

Rook

Rawle

et al. 2017

Frontline Gastroenterol

View full text Add to dashboard Cite

show abstract

The utility of faecal calprotectin to predict post-operative recurrence in Crohńs disease

Abstract: Faecal calprotectin predicts endoscopic recurrence in CD patients who have gone through surgery, however the cut-off point is still a problem so we cannot recommend calprotectin as a substitute of colonoscopy for CD monitoring and treatment adjustment.

Cited by 18 publications

References 31 publications

From bench to bedside: Fecal calprotectin in inflammatory bowel diseases clinical setting

From bench to bedside: Fecal calprotectin in inflammatory bowel diseases clinical setting

Is fecal calprotectin an accurate marker in the management of Crohn's disease?

Validation of a care pathway for the use of faecal calprotectin in monitoring patients with Crohn's disease

Contact Info

Product

Resources

About